文献速递湿疹皮炎与荨麻疹

Lebrikizumab治疗环孢素A控制不佳或不适用环孢素A的中重度特应性皮炎患者:安慰剂对照随机IIIb期研究(ADvantage)

Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage).
PubMed 文献 · Br J Dermatol · 2025-01-01

ADvantage研究纳入331例有环孢素A(CsA)应答不足史或不适用CsA的中重度特应性皮炎(AD)成人及青少年患者,按2:1随机接受Lebrikizumab 250 mg联合外用糖皮质激素(TCS)或安慰剂联合TCS皮下注射每2周一次,16周诱导期后所有患者接受Lebrikizumab 250 mg每2周一次开放标签维持治疗36周。第16周Lebrikizumab组EASI 75应答率显著高于安慰剂组(68.4% vs 40.8%,P<0.001),至第52周EASI 75和EASI 90应答率分别进一步升至88.9%和71.7%,安全性特征与已知一致。

要点

  • 对于CsA应答不足或不适用CsA的中重度AD患者,Lebrikizumab联合TCS第16周EASI 75达68.4%,显著优于安慰剂联合TCS的40.8%。
  • 第52周时,接受Lebrikizumab治疗(联合或不联合TCS)的患者EASI 75达88.9%、EASI 90达71.7%,瘙痒NRS≥4分改善达71.3%。
  • 第16周严重不良事件和导致停药的治疗中出现的不良事件(TEAE)发生率低且两组相似,至第52周仍保持较低水平。

核心结论

  • 在有CsA应答不足史或不适用CsA的中重度AD成人及青少年患者中,Lebrikizumab 250 mg每2周一次联合TCS在第16周显著改善AD体征和症状,且获益维持和/或进一步改善至第52周。
  • 安全性特征与已知的Lebrikizumab安全性特征一致。

研究设计与样本

  • 安慰剂对照、随机、IIIb期临床研究(ADvantage;NCT05149313)。
  • 共随机331例患者,其中220例接受Lebrikizumab联合TCS,111例接受安慰剂联合TCS。
  • 患者按2:1随机接受Lebrikizumab 250 mg联合TCS(基线及第2周给予500 mg负荷剂量)或安慰剂联合TCS,皮下注射,每2周一次,持续16周诱导期;随后所有患者接受Lebrikizumab 250 mg每2周一次开放标签维持治疗36周(TCS由研究者酌情使用)。
  • 主要终点为第16周达到湿疹面积和严重度指数较基线改善≥75%(EASI 75)的患者比例。

主要发现

  • 第16周,Lebrikizumab组达到EASI 75的患者比例显著高于安慰剂组(68.4% vs 40.8%;P<0.001)。
  • 第16周,Lebrikizumab组达到EASI 90的患者比例高于安慰剂组(42.9% vs 20.8%;P<0.001)。
  • 第16周,Lebrikizumab组达到研究者总体评估(IGA)清除/几乎清除且较基线改善≥2分的患者比例高于安慰剂组(42.0% vs 24.5%;P<0.01)。
  • 第16周,Lebrikizumab组达到瘙痒数字评定量表(NRS)改善≥4分的患者比例高于安慰剂组(49.9% vs 29.7%;P<0.05)。
  • 第52周,接受Lebrikizumab治疗(联合或不联合TCS)的患者中,EASI 75和EASI 90应答率分别进一步增至88.9%和71.7%;64.4%达到IGA 0/1应答,71.3%达到瘙痒NRS改善≥4分。

关键数值与推荐

  • 第16周,Lebrikizumab联合TCS组vs安慰剂联合TCS组的TEAE发生率分别为62.3% vs 53.2%;第52周Lebrikizumab组为76.9%。
  • 第16周,严重不良事件发生率在Lebrikizumab组 vs 安慰剂组分别为1.4% vs 0.9%,导致停药的TEAE发生率分别为0.5% vs 0.9%。
  • 第52周,严重不良事件发生率为5.9%,导致停药的TEAE发生率为2.5%。

临床怎么用

  • 对于有CsA应答不足史或不适用CsA的中重度AD成人及青少年患者,Lebrikizumab 250 mg每2周一次联合TCS可作为治疗选择。
  • 治疗16周可见显著疗效,继续治疗至52周疗效可进一步改善,支持长期维持治疗。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Ciclosporin A (CsA) is approved for severe atopic dermatitis (AD), but its efficacy may not be optimal, and its toxicity limits longer-term use. The recently approved lebrikizumab has demonstrated robust efficacy and favourable safety in adults and adolescents with moderate-to-severe AD. OBJECTIVES: To evaluate the efficacy and safety of lebrikizumab combined with topical corticosteroids (TCS) in adults and adolescents with moderate-to-severe AD who had a history of inadequate response to CsA or for whom CsA was not medically advisable. METHODS: This was a placebo-controlled, randomized phase IIIb clinical study (ADvantage; NCT05149313). Patients were randomized 2 : 1 to receive either lebrikizumab 250 mg plus TCS (with a loading dose of lebrikizumab 500 mg at baseline and week 2) or placebo plus TCS, delivered subcutaneously, every 2 weeks (Q2W), for the 16-week induction period. Following this, all patients received lebrikizumab 250 mg Q2W during a 36-week open-label maintenance period (with TCS use at investigator discretion). The primary endpoint was the proportion of patients who achieved ≥ 75% improvement from baseline in Eczema Area and Severity Index (EASI 75) at week 16. RESULTS: In total, 331 patients were randomized, 220 to receive lebrikizumab plus TCS and 111 to receive placebo plus TCS. At week 16, a significantly higher proportion of the lebrikizumab group vs. the placebo group achieved EASI 75 (68.4% vs. 40.8%; P < 0.001). At week 16, a greater proportion of the treatment group achieved ≥ 90% improvement from baseline in EASI (EASI 90) (42.9% vs. 20.8%; P < 0.001), Investigator's Global Assessment of clear/almost clear skin (IGA 0/1) with ≥ 2-point improvement from baseline (42.0% vs. 24.5%; P < 0.01), and ≥ 4-point improvement in pruritus numeric rating scale (NRS) (49.9% vs. 29.7%; P < 0.05). At week 52, the proportion of patients treated with lebrikizumab with/without TCS who achieved EASI 75 and EASI 90 further increased to 88.9% and 71.7%, respectively; 64.4% achieved IGA 0/1 response and 71.3% achieved a ≥ 4-point improvement in pruritus NRS. The incidence of treatment-emergent adverse events (TEAEs) was 62.3% in the lebrikizumab plus TCS group vs. 53.2% in the placebo plus TCS group at week 16, and 76.9% in the lebrikizumab group at week 52. Serious adverse events and TEAEs leading to discontinuation at week 16 were low and similar in lebrikizumab vs. placebo groups (1.4% vs. 0.9% and 0.5% vs. 0.9%, respectively), and remained low at week 52 (5.9% and 2.5%, respectively). CONCLUSIONS: Lebrikizumab 250 mg Q2W combined with TCS significantly improved signs and symptoms of AD at week 16 in adults and adolescents with moderate-to-severe AD and history of inadequate response to CsA or for whom CsA was not medically advisable, and those benefits were maintained and/or further improved by week 52. Safety was consistent with the known lebrikizumab safety profile. Atopic dermatitis (AD), also known as eczema, is a common skin disease. AD affects up to 10% of adults and 20% of children worldwide. Symptoms include dry, inflamed and red itchy skin. People can thus experience poor quality of life, sleep disorders, anxiety or depression. Ciclosporin A (CsA) is a drug that suppresses the immune system. Doctors consider it a first treatment for severe AD. However, its benefits may not be good enough for all patients. Also, CsA has side effects, so people should use it only for a limited time. Lebrikizumab is a biological drug (a medication made from living cells or organisms). It was recently approved for people with eczema. We wanted to see how effective and safe the drug was for people with AD who cannot use CsA for medical reasons or because CsA is not effective for them. We aimed to test the drug combined with topical corticosteroid (TCS), a steroid cream applied to the skin to reduce inflammation. We did our study in nine different countries. We assigned patients randomly (by chance) to receive the drug or a placebo (a lookalike medicine containing no drug) every 2 weeks (Q2W) plus TCS for 16 weeks. After that, all patients received lebrikizumab Q2W for 36 weeks. Doctors added TCS if they decided symptoms were not well controlled. The results showed that after 16 weeks, people on lebrikizumab had a greater improvement in AD symptoms than those on placebo. Their symptoms further improved after 52 weeks of treatment. Lebrikizumab was as safe as expected based on previous information about the medicine. In summary, lebrikizumab was effective and safe for people with AD who could not use CsA.

来源:Br J Dermatol,查看原文。版权归原作者所有。

引用

  1. Warren RB, de Bruin-Weller M, Tsianakas A, et al. Efficacy and safety of lebrikizumab in adult and adolescent patients with moderate-to-severe atopic dermatitis inadequately controlled with or ineligible for ciclosporin A: a placebo-controlled, randomized phase IIIb clinical study (ADvantage). Br J Dermatol. 2025. PMID: 40985295. doi:10.1093/bjd/ljaf285

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。